The high expression levels of ZIC2 and JUNB were positively correlated and linked to a poor outcomes in NPC patients, implying that ZIC2, JUNB, and CD163 could be utilized as prognostic markers for NPC and as therapeutic targets for cancer immunotherapy. The gene discussed is JUNB; the disease is nasopharyngeal carcinoma.